Physician profile
Eugene M Saravitz
NPI 1346202330
$8,636.51
in general payments reported to CMS, 2019-2025
26 companies · $949 in 2025
The $949 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,504 · 2020: $1,117 · 2021: $1,353 · 2022: $1,719 · 2023: $792 · 2024: $1,201 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,942.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,015.52 | 2019-2022 | |
| Abbvie INC. | $1,892.98 | 2022-2025 | Lumigan, Alphagan P, Durysta |
| Sun Pharmaceutical Industries INC. | $992.77 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $703.89 | 2024-2025 | Xiidra, Miebo, Vyzulta |
| Alcon Vision LLC | $662.90 | 2020-2025 | Tryptyr, Rocklatan, Hydrus Microstent |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $438.26 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $273.21 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $245.57 | 2019-2023 | |
| New World Medical,INC. | $218.72 | 2021-2022 | |
| Sight Sciences, INC. | $197.27 | 2019-2022 | |
| Rxsight INC | $143.06 | 2022-2023 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal) |
| Alexion Pharmaceuticals, INC. | $142.64 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $123.50 | 2022 | |
| W. L. Gore & Associates, INC. | $110.85 | 2023 | Gore Viabahn Vbx Balloon Expandable Endo |
| Johnson & Johnson Surgical Vision, INC. | $82.72 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $79.69 | 2022-2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $66.56 | 2019-2021 | |
| Omeros Corporation | $62.13 | 2019-2021 | |
| Ocular Therapeutix, INC. | $37.64 | 2020 | |
| Glaukos Corporation | $34.62 | 2022-2025 | Idosetr |
| Tarsus Pharmaceuticals, INC. | $29.87 | 2024 | Xdemvy |
| Dompe US, INC. | $17.27 | 2025 | Oxervate |
| Merz North America, INC. | $17.19 | 2020 | |
| Thea Pharma INC. | $16.80 | 2025 | Iyuzeh |
| Horizon Therapeutics Plc | $16.04 | 2022 | |
| Shire North American Group INC | $14.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Saravitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.